SGF Drs. Caleb Kallen and Sunita Kulshrestha host webinars in March to educate information seekers on the impacts of Endometriosis and PCOS on fertility.

Women with known or suspected endometriosis, especially those with what is called stage 3 or 4 endometriosis (meaning significant lesions or adhesions that can cause anatomic distortion), we recommend a fertility evaluation sooner rather than later.

WASHINGTON (PRWEB)
March 03, 2020

In honor of Endometriosis Month and PCOS Advocacy Day in March, SGF physicians will offer support through two virtual webinars; information seekers can learn about the conditions and their respective impacts on fertility. SGF physicians will discuss when to seek help from a fertility specialist and will outline treatment options. Additional fertility topics offered through SGF’s March events include elective egg freezing, donor egg treatments, IVF, and “what to expect when you’re not expecting” (a guide to fertility testing and treatments).

Endometriosis is a common condition in which cells that ordinarily line the uterine cavity reside in the pelvis leading to cyclic pelvic pain, inflammation, and sometimes scarring in and around the Fallopian tubes. In support of those affected by endometriosis, and to honor Endometriosis Awareness Month, Sunita Kulshrestha, M.D., of SGF’s Waldorf, MD, office will host a virtual Endometriosis webinar on Thursday, March 26.

“While having endometriosis does not necessarily mean that one will experience infertility, those afflicted with the condition are at a higher risk of developing infertility,” says Dr. Kulshrestha. “Women with known or suspected endometriosis, especially those with what is called stage 3 or 4 endometriosis (meaning significant lesions or adhesions that can cause anatomic distortion), we recommend a fertility evaluation sooner rather than later.”

Polycystic ovary syndrome, or PCOS, is the most common endocrine condition in women and is associated with irregular or absent menstrual cycles and sometimes with unwanted hair growth (on the face or chest) and acne. In honor of PCOS Advocacy Days (March 11-12 on Capitol Hill, Washington, D.C.), Caleb Kallen, M.D., Ph.D., of SGF’s Chesterbrook and Philadelphia, PA, offices will host a virtual PCOS webinar on Tuesday, March 24.

“PCOS is one of the most common hormonal disorders in women of childbearing age and is estimated to affect nearly 10% of reproductive age women,” says Kallen. “Naturally, absent or irregular menstrual cycles makes it difficult or impossible to get pregnant without treatment. Fortunately, there are several effective (and affordable) treatments for PCOS. Our PCOS webinar seeks to eliminate some of the mysteries surrounding PCOS and to educate patients on how we can approach PCOS to help women conceive.”

While all SGF events are complimentary (*unless otherwise noted), interested parties must register to attend by visiting the SGF calendar of events.

March Modern Family Seminar

March 5 | Philadelphia, PA | Featuring SGF’s Brianna Schumacher, M.D.

Hosted by Vaysman Legal, the Modern Family Seminar will feature expert panelists discussing topics including egg freezing, donor egg, donor embryo, IVF, family law, LGTBQ family building, and how to access benefits in the workplace.

*Admission is $20-25.

March Egg Freezing Seminar

March 26 | New York, NY | Tomer Singer, M.D.

March Donor Egg Seminar

March 19 | New York, NY | Anate Brauer, M.D.

March “What to Expect When You’re Not Expecting” Seminars

March 4 | Towson, MD | Ricardo Yazigi, M.D.

March 5 | New York, NY | Anate Brauer, M.D.

March 5 | Lancaster, PA – Eden Resort | Melanie Ochalski, M.D.

March 11 | Fair Oaks, VA | Paulette Browne, M.D.

March 11 | Atlanta, GA | Mark Perloe, M.D.

March 12 | Rockville, MD | Joseph Doyle, M.D.

March Fertility Breakfast (informational drop-in hosted in a casual, public venue)

March 21 | Warrington, PA | Ryan Martin, M.D.

March Fertility Webinars

March 5 | IVF | Ricardo Yazigi, M.D.

March 12 | Getting Started | Wende Allen, PA-C

March 24 | PCOS | Caleb Kallen, M.D., Ph.D.

March 26 | Endometriosis | Sunita Kulshrestha, M.D.

If you are struggling to conceive, it may be time to see a fertility specialist. Contact the SGF New Patient Center at 1-877-971-7755 or complete a brief online form and get started on your path to parenthood.

To view SGF’s growing library of free, on-demand webinars, E-books, and other education resources on topics such as endometriosis, PCOS, low-tech treatment options, weight and infertility, and much more, visit https://www.shadygrovefertility.com/resources/educational-resources.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

The approval of Pizensy represents a major step forward in treatment options for CIC. Pizensy will be the only FDA approved product which the patient can self-titrate based on their own results for stool consistency, said Jack A. Di Palma, M.D.

BRAINTREE, Mass. (PRWEB)
March 02, 2020

Sebela Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Pizensy™ (lactitol) for oral solution for the once-daily treatment of chronic idiopathic constipation (CIC) in adults. Pizensy is a simple monosaccharide sugar alcohol that exerts an osmotic effect, causing the influx of water into the small intestine leading to a laxative effect.

“The approval of Pizensy represents a major step forward in treatment options for CIC. Pizensy will be the only FDA approved product which the patient can self-titrate based on their own results for stool consistency,” said Jack A. Di Palma, M.D., Professor of Medicine and Fellowship Program Director of the Division of Gastroenterology at the University of South Alabama College of Medicine and Past-President of the American College of Gastroenterology. “Pizensy will allow practitioners and patients to jointly take control of their condition using a product with the same proven and safe mechanism of action as we have seen in bowel prep products such as SUPREP® Bowel Prep Kit.”

Unlike current prescription treatments which are solid oral doses, Pizensy is mixed with the patient’s fluid of choice, e.g., water, juice, coffee, tea or soda, and taken once a day at whatever time the patient prefers, preferably with food. Pizensy allows patients to adjust the dose of the product. In the clinical trials versus placebo, approximately 25% of patients were able to at least temporarily reduce their dose.

Pizensy is expected to be available in the U.S. in the second half of 2020. Pizensy is a New Chemical Entity and is expected to have patent protection until 2037. Sebela intends to commercialize Pizensy in the U.S. with a marketing partner and has received preliminary expressions of interest from a number of interested parties.

CIC is a complex, functional GI disorder defined by symptoms including fewer than three bowel movements a week and hard-to-pass or incomplete bowel movements, for which there is no identifiable cause.1,2 CIC affects approximately 33 million Americans and an estimated 14 percent of the global population.2 Almost 4.7M brand prescriptions were written for products indicated for CIC in 2019, representing gross sales of $2.36B and growth rates of +6% and +16% versus 2018 respectively.3

The efficacy and safety of Pizensy were evaluated in three Phase 3 clinical trials which included more than 1,400 patients. These included a 6-month, double-blind, placebo-controlled study, a 12-week, blinded head to head study versus lubiprostone (AMITIZA®) and a 12-month, open-label, chronic use study.

Over the first 12-week course of treatment, patients treated with Pizensy achieved a significantly greater efficacy response compared to placebo (26% vs. 13%, p less than 0.001). This response was sustained in the Pizensy group during Weeks 13 to 24. In both pivotal trials, efficacy responders were defined as patients who had at least three complete spontaneous bowel movements (CSBMs) in a given week and an increase of at least one CSBM over baseline in the same week for at least nine out of 12 weeks, including at least three of the last four weeks.

Over course of treatment, patients who received Pizensy had statistically significant improvements as compared to placebo in stool frequency (as measured by the number of spontaneous and complete spontaneous bowel movements per week) and stool consistency (as measured by the Bristol Stool Form Scale).

The most common adverse event reported in the clinical trials versus placebo was Upper Respiratory Tract Infection at a rate of 9% compared to 6% of patients treated with placebo. Other adverse events reported at a lower frequency include flatulence and diarrhea. The rates of diarrhea and severe diarrhea were similar between the Pizensy and placebo groups. Overall discontinuation rates were low among patients treated with Pizensy at 4% as compared to placebo at 3%.

Indications and Usage

Pizensy is indicated for chronic idiopathic constipation in adults.

IMPORTANT SAFETY INFORMATION

Pizensy™ is contraindicated in patients known or suspected mechanical gastrointestinal obstruction or galactosemia.

The most common adverse reactions observed when taking Pizensy (greater than 3%)%) are upper respiratory tract infection, flatulence, diarrhea, Increased blood creatinine phosphokinase, abdominal distension and high blood pressure.

The following adverse reactions have been identified during post-approval use of lactitol outside the United States, hypersensitivity reactions, including rash and pruritus.

Pizensy may reduce the absorption of concomitantly administered oral medications. Administer oral medications at least 2 hours before or 2 hours after Pizensy.

Please click here for Full Prescribing Information

About Chronic Idiopathic Constipation (CIC)

CIC affects approximately 14 percent of the global population, disproportionately affecting women and older adults.2 People with CIC have persistent symptoms of difficult and infrequent bowel movements.1 In addition to physical symptoms including abdominal bloating and discomfort, CIC can adversely affect an individual’s quality of life, including increasing stress levels and anxiety.1

About Pizensy™

Pizensy™ (lactitol) for oral solution is a once-daily product wherein 20 grams of the product is mixed with 4 to 8 ounces of fluid, e.g., water, juice or soda for the treatment of chronic idiopathic constipation in adults. If the patient experiences loose stools the dose of Pizensy™ can be lowered to 10 grams mixed with 4 to 8 ounces of fluid.

About Sebela Pharmaceuticals

Sebela is a private, US-focused growth-oriented specialty pharmaceutical company developing and commercializing gastroenterology, women’s health and dermatology prescription products. The company is a pioneer in gastroenterology therapy for bowel cleansing prior to colonoscopy having developed multiple innovative prescription bowel prep and constipation products such as GoLYTELY®, NuLYTELY®, MiraLAX® and SUPREP® Bowel Prep Kit. Sebela has numerous further advances in bowel prep therapy in late-stage clinical development including one NDA currently under review by the FDA. Sebela also has two next-generation Intra-Uterine Devices (IUDs) for contraception in development which holds the promise of better patient experience in addition to excellent efficacy.

Sebela has offices in Roswell, GA; Braintree, MA; and Dublin Ireland, has annual net sales of approximately $250 million and has grown to over 300 employees through strategic acquisitions and organic growth. Sebela’s products in Gastroenterology and Dermatology maintain number one market share positions in the marketplace as branded prescription products for their indications.3

Please visit sebelapharma.com for more information.

Forward-Looking Statement

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebela Pharmaceuticals under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the development, launch, introduction and commercial potential of Pizensy; growth and opportunity, including peak sales and the potential demand for Pizensy, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third-party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash used for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Sebela does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law.

1Thomas R, Luthin D. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Pharmacotherapy Pub. 2015; 613-630.

2 Suares NC, Ford AC. Prevalence of, and risk factors for chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(9): 1582-1591.

3IQVIA. National Prescription Audit Report. December 2019.

AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc.

MiraLAX is a registered trademark of Bayer Healthcare LLC

SOURCE: Sebela Pharmaceuticals

Sebela Pharmaceuticals

Jai Wall

VP, Corporate Affairs

jai.wall@sebelapharma.com

“Companies like NucleusHealth are critical in helping healthcare organizations use technology to address industry challenges and seize opportunities to impact people’s lives in a positive way.”

SAN DIEGO (PRWEB)
March 02, 2020

NucleusHealth, a medical image management technology company and teleradiology services provider, announced their appearance inside the Microsoft Azure for Healthcare booth at the 2020 Healthcare Information Management Systems Society (HIMSS) Global Health Conference and Exhibition. The company will showcase its Nucleus.io platform that is disrupting the imaging space with its cloud native PACS solution.

NucleusHealth chose Microsoft Azure to power the Nucleus.io medical image management platform because of its dependable security and longstanding presence in the healthcare industry. “NucleusHealth delivers its Nucleus.io platform via Microsoft Azure to nearly 7,000 image management organizations. Using a cloud-based platform also enables our teleradiologists to access and read 1.3 million studies per year,” says Claude Hooton, NucleusHealth President and Chief Operating Officer. “We live and breathe the solution that we provide to clients. Azure is a proven cloud provider that allows us to enhance our own cloud platform in day-to-day operations.”

“We’re pleased NucleusHealth is joining us at HIMSS to showcase how technology is helping healthcare organizations succeed in transforming patient care and their businesses. Microsoft Azure helps unify people, devices, apps and information responsibly by prioritizing compliance, security and trust,” said Gareth Hall, director of business strategy for Worldwide Healthcare at Microsoft Corp. “Companies like NucleusHealth are critical in helping healthcare organizations use technology to address industry challenges and seize opportunities to impact people’s lives in a positive way.”

NucleusHealth will be demonstrating the flexibility of its image management platform and how organizations can utilize the Nucleus.io platform to enhance workflows, elevate user experience, reduce IT burden, and eventually replace aging enterprise imaging systems altogether. Claude Hooton, NucleusHealth President and COO will also be presenting in a Lunch and Learn session to show how Nucleus.io cooperates in the market by enabling artificial intelligence and machine learning applications for imaging needs through the usage of standards.

The Nucleus.io cloud-based image management platform is comprised of modular solutions. They are all completely in a web browser and provide image exchange, remote reading, downtime PACS, cloud PACS, and a platform-as-a-service for enabling medical software applications. Nucleus.io is one of the first imaging solutions to use client-side rendering paired with proprietary adaptive streaming protocols to bypass any latency issues currently experienced with all other cloud solutions. This approach allows for the viewing of large medical images in a browser with the same performance as on-premise workstations. More information will be available throughout HIMSS 2020 in Orlando at the Microsoft Azure exhibit, booth No. 2300, Orange County Convention Center.

About NucleusHealth

NucleusHealth is advancing patient care through innovation in cloud-based medical image management, facilitating a global image exchange accessible by patients, physicians and healthcare networks. NucleusHealth licenses its Nucleus.io software as a service (SaaS) and web-scale platform as a service (PaaS) technologies to healthcare organizations and companies across the globe. The company’s StatRad teleradiology service was founded in 1996, by radiologists for radiologists, and develops and implements forward-thinking solutions for radiology groups. For more information, call us at +1(858)251-3400, visit us at http://www.nucleushealth.io, or connect with us on Twitter or LinkedIn.

Share article on social media or email:

Patient Experience Journal

In association with The Beryl Institute, Patient Experience Journal announces the inaugural 2019 Patient Experience Journal (PXJ) award recipients.

NASHVILLE, Tenn. (PRWEB)
March 02, 2020

In association with The Beryl Institute, Patient Experience Journal announces the inaugural 2019 Patient Experience Journal (PXJ) award recipients. The annual awards celebrate important contributions to the literature and articles of impact in research and practice. They also introduce groundbreaking authors who are working to expand evidence and insights on patient experience and the human experience in healthcare.

The winners are selected from the articles published in PXJ and chosen by the Editorial Board. Award recipients will be celebrated during a ceremony Tuesday, April 21, 2020 at The Beryl Institute Patient Experience Conference in Orlando, Florida.

The winning articles are:

• 
  ARTICLE OF THE YEAR (Volume 6)
• “Anyone can co-design?”: A case study synthesis of six experience-based co-design (EBCD) projects for healthcare systems improvement in New South Wales, Australia
• Tara L. Dimopoulos-Bick, Agency for Clinical Innovation, New South Wales, Australia
• Claire O’Connor, Agency for Clinical Innovation, New South Wales, Australia
• Jane Montgomery, Agency for Clinical Innovation, New South Wales, Australia
• Tracey Szanto, Agency for Clinical Innovation, New South Wales, Australia
• Marion Fisher, Agency for Clinical Innovation, New South Wales, Australia
• Violeta Sutherland, Agency for Clinical Innovation, New South Wales, Australia
• Helen Baines, Hunter New England Local Health District, NSW, Australia
• Phillip Orcher, Agency for Clinical Innovation, New South Wales, Australia
• John Stubbs, Agency for Clinical Innovation, New South Wales, Australia
• Lynne Maher, Ko Awatea Counties Manukau Health, Auckland, New Zealand
• Raj Verma, Agency for Clinical Innovation, New South Wales, Australia
• Victoria J. Palmer, The Department of General Practice, Melbourne Medical School, The – University of Melbourne, Australia
• BEST ARTICLE – EMERGING SCHOLAR (Volume 6)
• Engaging under- and/or never-engaged populations in health services: A systematic review
• Lesley Moody, University Health Network
• Erica Bridge, Cancer Care Ontario
• Vidhi Thakkar, McMaster University
• Naomi Peek, Cancer Care Ontario
• Tanvi Patel, Cancer Care Ontario
• Suman Dhanju, Cancer Care Ontario
• Simron Singh, Sunnybrook Health Sciences Centre
• BEST ARTICLE – PRACTITIONER (Volume 6)
• Using experience-based design to understand the patient and caregiver experience with delirium
• Lauren Russ, Virginia Mason
• Jennifer Phillips, Virginia Mason
• Val Ferris, Virginia Mason
• Amy London, Virginia Mason
• Logan Kendall, University of Washington – Seattle Campus
• Craig Blackmore, Virginia Mason
• MOST IMPACTFUL ARTICLE (Last 5 Volumes)
• Patient partnership in quality improvement of healthcare services: Patients’ inputs and challenges faced
• Marie-Pascale Pomey, University of Montreal
• Hassiba Hihat, University of Montreal
• May Khalifa, University of Montréal
• Paule Lebel, University of Montréal
• André Néron, University of Montréal
• Vincent Dumez, University of Montréal

“We are excited to introduce the PXJ Awards and announce this year’s recipients. The articles being recognized represent the rigor, thoughtfulness and vision seen in all the pieces published in the journal,” said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute. “PXJ remains committed to elevating the work of our authors and honoring the interest of our readers by bringing together a broad and comprehensive selection of cutting-edge articles from around the world. We congratulate our inaugural awardees and invite all to consider PXJ as the place to reach the broadest audience and have the greatest impact with your work in elevating the evidence on patient experience.”

PXJ publishes three times annually in April, November and a special topic issue in July. Submissions are accepted on an ongoing basis. All submissions should adhere to the requested submission types and author guidelines.

PXJ is also accepting submissions for the 2020 Special Issue on Patient & Family Experience in Behavioral Health. The deadline for submissions for that issue is April 1, 2020. Learn more: https://pxjournal.org/journal/vol6/iss2/16

###

About Patient Experience Journal:

Patient Experience Journal (PXJ) is a peer-reviewed, open-access journal published in association with The Beryl Institute. Read in over 200 countries and territories, PXJ is committed to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation on patient experience.

About The Beryl Institute:

The Beryl Institute is a global community of practice committed to elevating the human experience in healthcare. We believe human experience is grounded in experiences of patients & families, those who work in healthcare and the communities they serve.

We define the patient experience as the sum of all interactions, shaped by an organization’s culture, that influence patient perceptions across the continuum of care.

Share article on social media or email:

“Participating in the Health Value Awards demonstrates healthcare companies and providers are not only committed to providing high-quality, value-based healthcare, but are ready to lead the industry in a new, exciting, and necessary direction,” said RD Whitney, CEO of Validation Institute.

PORTSMOUTH, N.H. (PRWEB)
March 02, 2020

The Health Value Awards presented by Validation Institute is pleased to recognize the final list of finalists for the 2020 awards program. Now in its third year, the Health Value Awards continues to recognize outstanding services, products, and programs across 30+ categories spanning the healthcare industry. In addition to these finalist, seven individuals will be recognized for outstanding contributions to the industry with an Honorary Award.

“It is with great pleasure we announce the Health Value Award finalists and our 2020 Honorary award winners. Participating in the Health Value Awards demonstrates healthcare companies and providers are not only committed to providing high-quality, value-based healthcare, but are ready to lead the industry in a new, exciting, and necessary direction,” said RD Whitney, CEO of Validation Institute.

Health Value Award candidates complete a lengthy and rigorous application process, particularly those nominated in a peer-review category who participate in an in-depth evaluation to ensure the accuracy of performance claims. This year’s finalists are:

Peer-reviewed Finalists

• 
  Abacus Health Solutions – Diabetes Care Rewards
• Allergychoices – Allergy Control Program
• Apta Health, LLC
• ARC Fertility
• Blossom Bariatrics – Fast Track Program
• BlueCross BlueShield of South Carolina – Population Health Management Programs
• Bockmann Technique
• Drexi
• eMindful – eM Life
• EmpiRx Health
• Fast Health
• finHealth, Inc. – finHealth Navigator
• freshbenies
• Green Imaging, LLC
• MedEncentive – Mutual Accountability and Information Therapy (MAIT)
• Midlands Orthopaedics & Neurosurgery – Outpatient Surgery Program
• MindSciences, Inc. – Unwinding Anxiety
• MMS Analytics d/b/a MyMedicalShopper – MyMedicalShopper
• NOVA Healthcare Administrators – Health Plan Performance Management
• PACE, Inc. – Orthopedic Surgery Commercial Insurance Bundles for Total Hip and Knee Replacement
• Proactive MD – Advanced Primary Care
• Remedy Partners – Remedy Episode of Care Management Program
• Rx Manage
• Suquino – Saffron
• Solveglobal, LLC – Musculoskeletal Disorders/Conditions (MSD) Health Solutions
• Texas Medical Management – Free Market Surgery
• The Leapfrog Group – Leapfrog Hospital Safety Grade
• Tria Health – Pharmacy Advocate Program
• TrueLifeCare
• University of Texas at Austin – Musculoskeletal Institute at UT Health Austin
• U.S. HealthCenter, Inc. – PredictiMed
• Virta Health
• Virtual Physical Therapists
• Wildflower Health – Maternity Digital Application

Non-peer-reviewed Finalists

• 20Lighter
• Alegeus – Smart Account
• AmeriBen/IEC Group
• Anthem Blue Cross Blue Shield – Cooperative Care
• Brighton Health Plan Solutions – Create
• Carmel Clay Schools – Carmel Clay Schools Wellness Center
• Concord Management Resources – Members Health Plan New Jersey
• Connect Healthcare Collaboration
• Connecticut Joint Replacement Institute – The Step Ahead Plan
• City of Austin, TX – PE Anytime Program
• Decent
• DispatchHealth – Clinical Service Line | Advanced Care and Extended Care
• EZaccessMD
• Healthcare Transformation Consortium
• Health-E Commerce
• IM Health – Worldwide Centers of Excellence for Oncology
• Medliminal
• Metro Nashville Public Schools – Teachers’ Health Plan
• NYU Langone Health – Transform Diabetes Care
• Scripta Insights
• Simpara – Simpara Direct
• SmartHealth PayCard
• Spire – HR Journey Builder and Periscope Analytics
• StableRise – EMR Workstation
• StanData Technology – StanData App
• VillagePlan
• youturn

Honorary Award Recipients

Hall of Fame

• Marty Makary, MD
• Clayton Christensen

Lifetime Achievement | Clinical Care

• Keith Smith, Founder & CEO, Surgery Center of Oklahoma

Lifetime Achievement | Health Benefits Innovation

• Dave Chase, Co-founder & CEO, Health Rosetta

Outstanding 2020 Benefits Advisor/Broker

• Jeffrey Hogan, Northeast Regional Manager, Rogers Benefit Group

Outstanding 2020 Employer/Union Benefits Manager

• Katie Archer, Director, Health and Welfare Plans Benefits Design, Planning, and Analysis, The Hartford

Outstanding 2020 Corporate Senior Leader, Health Benefits

• Lisa Woods, Senior Director of Benefits, Walmart

Winners will be announced live at the Health Value Awards ceremony at the Wardman Park Hotel in Washington, D.C. on Sunday, March 29, 2020 as part of Health Value Day (co-located with World Health Care Congress).

About the Validation Institute:

Validation Institute is an independent, objective, 3rd party organization on a mission to improve the quality and cost of healthcare. Based in Portsmouth, N.H., the organization is made up of a network of health benefits purchasers, health benefits advisors, and healthcare solution providers focused on delivering better health value and stronger outcomes than conventional healthcare. http://www.validationinstitute.com

Share article on social media or email:

Datex logo

CLEARWATER, Fla. (PRWEB)
March 02, 2020

For the 13th consecutive year, Microsoft-based software developer Datex was named a 2019 “Top 100 Logistics IT Provider” by Inbound Logistics Magazine. The distinction was made after the Inbound Logistics editorial section team evaluated the surveys on IT capabilities submitted by over 400 IT providers.

Each year, Inbound Logistics Magazine surveys the supply chain logistics technology market for its special edition which focuses on technology. The 2019 Inbound Logistics technology edition includes information on what is driving logistics IT demand including:

• E-commerce
• Omnichannel retail
• Warehouse management systems
• Blockchain
• Business intelligence
• Integration
• Increased automation
• Positioning technologies
• Freight bidding

Datex FootPrint® WMS can be used for any type of commodity, and is especially effective for regulated goods including pharmaceuticals, food and beverages and precious metals. The Datex warehouse management system is workflow-driven and incorporates query capabilities for added flexibility. Datex can train client internal IT resources to configure workflows and create customized reports and dashboards to help reduce implementation and ongoing costs.

Datex FootPrint® WMS includes labor management and features the most flexible 3PL WMS billing module in the industry, cartonization, kitting and assembly and a suite of cost-saving functionality for warehouse operations. The award-winning software is in use across the world in 3PL warehouses, e-commerce omnichannel fulfillment operations, cold storage/refrigerated warehouses and distribution centers.

About Inbound Logistics

Since its inception in 1981, Inbound Logistics’ educational mission is to illustrate the benefits of demand-driven logistics practices, give companies the knowledge to help them match the inbound flow of materials to their demand, and align their business process to support that shift. Inbound Logistics offers real-world examples and decision support to guide businesses to efficiently manage logistics, reduce and speed inventory, and offset rising transport costs, supporting business scalability across their value chain. More information about demand-driven logistics practices is available at http://www.inboundlogistics.com.

About Datex

For over 42 years, Datex has helped supply chain businesses to operate more efficiently and productively using cutting edge technology. As a Microsoft Gold level partner for Software Application Development, Datex is considered to be in the top 1% of the 640,000 Microsoft partners worldwide. For more information on Datex software, hardware and managed services, please visit the Datex website http://www.datexcorp.com/.

Share article on social media or email:

Urgent Care Association (UCA)

“Consumer expectations and preferences are changing every day, and so is the healthcare landscape. We redesigned our annual convention to help providers evolve their practices in ways that will best serve patients in the future,” said Laurel Stoimenoff, PT, CHC, CEO of UCA.

WARRENVILLE, Ill. (PRWEB)
March 02, 2020

The nation’s leading experts in on-demand care will convene at the Paris Hotel in Las Vegas, May 3-6, 2020, for the UCA2020 Urgent Care Convention. Presented by the Urgent Care Association (UCA) and the College of Urgent Care Medicine (CUCM), the event is focused on delivering “something (almost) completely different” for attendees, restructuring the annual conference’s content to encourage active discussions on how to innovate on-demand healthcare for the future. Registration deadlines are fast approaching, with tuition rates increasing after March 26 and the Paris Hotel room block closing on April 1, 2020.

“Consumer expectations and preferences are changing every day, and so is the healthcare landscape. We redesigned our annual convention to help providers evolve their practices in ways that will best serve patients in the future,” said Laurel Stoimenoff, PT, CHC, CEO of UCA. “Our convention will bring to light important topics facing the industry, such as providing the best care for LGBTQ patients, and exploring ways to push the industry forward with new technologies and partnerships.”

According to the most recent UCA Benchmarking Report, the urgent care industry grew by nearly 10% in 2019. UCA strives to support the success of the industry and promote continued growth, so UCA2020 will feature innovative sessions, hands-on workshops and engaging lectures for both clinical and practice management professionals. Brand new pre-conference activities will feature an accreditation workshop to discover how to obtain or maintain UCA Accreditation, as well as a two-day clinic start-up pre-con on how to set up an urgent care operation. To kick off the convention, and directly following the opening general session, the HIPPO Education Team will be bringing their interactive roadshow, designed to challenge how clinicians think about their team practices.

The Now and Next in Urgent Care:

The UCA2020 Convention will feature an equal focus on what’s now and what’s next. Sessions with many new out-of-the-box thinkers will cover topics including better onboarding, financial modeling for new services, revenue cycle oversight and regulatory changes. Some sessions will count towards the 62 credit hours required to achieve Certified Urgent Care Management Professional (CUCMP) certification.

“The urgent care industry continues to change at a rapid pace, and this year’s sessions will cover forward-thinking content and ground-breaking tools to improve current practices and reframe urgent care for the future,” said Richard Park, MD, UCA board president, founder of CityMD. “It is more important than ever to educate our leaders and providers on the latest advancements and pioneering ideas to pave the way for diversified on-demand medicine.”

Advancing Innovations in On-Demand Care:

Advanced Innovations sessions will take attendees into the future of strategy development, provider engagement, emerging technologies, care models and payment mechanisms, leadership, hospitality, marketing, and the next wave of mergers and acquisitions.

During two back-to-back New2Know sessions, attendees will learn more about emerging models in on-demand healthcare, such as telemedicine/house call hybrids, direct-to-specialist e-referral systems and more. With TED-style talks and a Q&A with the New2Know innovators and payer experts, attendees will analyze their organization’s ability to adopt or adapt similar models, as well as recognize the payer trends influencing urgent care centers today.

In addition, attendees will have the chance to tap the expertise of Las Vegas’ very own Caesar’s Palace entertainment team, who will discuss how to translate hospitality-driven philosophies into urgent care patient experience. Also taking place will be a one-of-a-kind industry hackathon, where the top minds in on-demand care will come together to explore complex issues and brainstorm new solutions for 2020 and beyond.

Throughout the event, UCA2020 participants will be exposed to a myriad of advanced strategic approaches for enhancing their practices, including:

• How to provide the best care for LGBTQ patients
• The importance of antibiotic stewardship in urgent care
• End-to-end patient experience
• The nuts and bolts of running a successful urgent care today
• Pediatrics-focused sessions on ultrasound, measles, pain reduction and positioning techniques, and breastfeeding

Several keynote speakers will share insights on the latest industry trends, from disrupting the status quo to deploying emerging technologies strategically in the on-demand space. For the closing keynote, Dr. Zeev Neuwirth, award-winning podcast host and author of Reframing Healthcare, will share his vision for retail healthcare today, tomorrow and into the future, featuring Marcus Osborne, vice president of health transformation at Walmart.

For more information about the UCA2020 Convention & Expo and to register for the event, please visit http://www.ucaoa.org/Convention.

About the Urgent Care Association

The Urgent Care Association (UCA) is a membership association of leaders, providers and suppliers in the field of on-demand, consumer-focused health care. UCA advances the industry and supports member success through advocacy, research, education, collaboration and high standards of care. The association maintains an active online presence and member community for daily exchange of best practices. For more information, visit http://www.ucaoa.org.

Share article on social media or email:

OxyPAP from D-R Burton Healthcare

The OxyPAP features a breakthrough in hygiene, a critical need for respiratory patients at risk for infection, because the OxyPAP’s convenient handle converts to a hygienic mouthpiece cover when not in use.

FARMVILLE, N.C. (PRWEB)
March 02, 2020

D•R Burton Healthcare Products LLC presents the OxyPAP™ Positive Airway Pressure (PAP) device delivering oxygen flow with unique hygiene protection for patients needing lung expansion therapy. The OxyPAP uniquely can be used with other D•R Burton products to deliver oxygen flow for patients needing secretion clearance during Oscillating Positive Expiratory Pressure (OPEP) therapy.

“The OxyPAP features a breakthrough in hygiene, a critical need for respiratory patients at risk for infection” according to Dennis Cook, BSRT, RRT, CEO of D•R Burton, because the OxyPAP’s convenient handle converts to a hygienic mouthpiece cover when not in use. The OxyPAP is used to help patients expand their lungs and also delivers supplemental oxygen especially useful for patients who cannot take a deep breath during respiratory therapy.

Besides providing lung expansion and oxygen flow for patients via PAP therapy, the OxyPAP can also help patients clear secretions by working in conjunction with other D•R Burton OPEP devices. According to Cook, “the component design of the OxyPAP allows clinicians to tailor effective respiratory therapy to individual patient needs while providing economic value to healthcare providers.

About D•R Burton Healthcare Products LLC

D•R Burton Healthcare Products LLC, innovators in medical devices, was founded by clinicians with deep expertise in respiratory care and anesthesia. Together we design, develop and market medical device products that allow patients to heal faster and provide value to our partners and consumers. Our unique clinical perspective drives our unwavering commitment to provide clinicians and their patients with a world class user experience. For more information, please visit http://www.drburtonhpi.com

Share article on social media or email: